{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["CYP450", "herb-drug interactions", "recombinant human CYPs", "reversible inhibition", "time-dependent inhibition"]], "OtherID": [], "CitationSubset": ["IM"], "InvestigatorList": [], "SpaceFlightMission": [], "GeneralNote": [], "OtherAbstract": [], "PMID": "26891286", "DateCompleted": {"Year": "2016", "Month": "10", "Day": "24"}, "DateRevised": {"Year": "2020", "Month": "12", "Day": "09"}, "Article": {"ArticleDate": [{"Year": "2016", "Month": "02", "Day": "16"}], "ELocationID": ["211", "10.3390/molecules21020211"], "Language": ["eng"], "Journal": {"ISSN": "1420-3049", "JournalIssue": {"Volume": "21", "Issue": "2", "PubDate": {"Year": "2016", "Month": "Feb", "Day": "16"}}, "Title": "Molecules (Basel, Switzerland)", "ISOAbbreviation": "Molecules"}, "ArticleTitle": "Inhibition of CYP2B6 by Medicinal Plant Extracts: Implication for Use of Efavirenz and Nevirapine-Based Highly Active Anti-Retroviral Therapy (HAART) in Resource-Limited Settings.", "Abstract": {"AbstractText": ["Highly active antiretroviral therapy (HAART) has greatly improved health parameters of HIV infected individuals. However, there are several challenges associated with the chronic nature of HAART administration. For populations in health transition, dual use of medicinal plant extracts and conventional medicine poses a significant challenge. There is need to evaluate interactions between commonly used medicinal plant extracts and antiretroviral drugs used against HIV/AIDS. Efavirenz (EFV) and nevirapine (NVP) are the major components of HAART both metabolized by CYP2B6, an enzyme that can potentially be inhibited or induced by compounds found in medicinal plant extracts. The purpose of this study was to evaluate the effects of extracts of selected commonly used medicinal plants on CYP2B6 enzyme activity. Recombinant human CYP2B6 was used to evaluate inhibition, allowing the assessment of herb-drug interactions (HDI) of medicinal plants Hyptis suaveolens, Myrothamnus flabellifolius, Launaea taraxacifolia, Boerhavia diffusa and Newbouldia laevis. The potential of these medicinal extracts to cause HDI was ranked accordingly for reversible inhibition and also classified as potential time-dependent inhibitor (TDI) candidates. The most potent inhibitor for CYP2B6 was Hyptis suaveolens extract (IC50 = 19.09 \u00b1 1.16 \u00b5g/mL), followed by Myrothamnus flabellifolius extract (IC50 = 23.66 \u00b1 4.86 \u00b5g/mL), Launaea taraxacifolia extract (IC50 = 33.87 \u00b1 1.54 \u00b5g/mL), and Boerhavia diffusa extract (IC50 = 34.93 \u00b1 1.06 \u00b5g/mL). Newbouldia laevis extract, however, exhibited weak inhibitory effects (IC50 = 100 \u00b1 8.71 \u00b5g/mL) on CYP2B6. Launaea taraxacifolia exhibited a TDI (3.17) effect on CYP2B6 and showed a high concentration of known CYP450 inhibitory phenolic compounds, chlorogenic acid and caffeic acid. The implication for these observations is that drugs that are metabolized by CYP2B6 when co-administered with these herbal medicines and when adequate amounts of the extracts reach the liver, there is a high likelihood of standard doses affecting drug plasma concentrations which could lead to toxicity."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Division of Human Genetics, Department of Pathology &amp; Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Anzio Road, Observatory, Cape Town 7925, South Africa. THMNIC023@myuct.ac.za."}, {"Identifier": [], "Affiliation": "School of Medical Sciences, University of Cape Coast, Cape Coast, PMB, Ghana. THMNIC023@myuct.ac.za."}], "LastName": "Thomford", "ForeName": "Nicholas E", "Initials": "NE"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Division of Clinical Pharmacology, Faculty of Medicine and Health Sciences, University of Stellenbosch, Cape Town 7602, South Africa. charzos@yahoo.com."}], "LastName": "Awortwe", "ForeName": "Charles", "Initials": "C"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "International Center for Genetic Engineering and Biotechnology (ICGEB), Cape Town component, Faculty of Health Sciences, University of Cape Town, Anzio Road, Observatory, Cape Town 7925, South Africa. kd.dzobo@uct.ac.za."}, {"Identifier": [], "Affiliation": "Division of Medical Biochemistry, Faculty of Health Sciences, University of Cape Town, Anzio Road, Observatory, Cape Town 7925, South Africa. kd.dzobo@uct.ac.za."}], "LastName": "Dzobo", "ForeName": "Kevin", "Initials": "K"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Medical Sciences, University of Cape Coast, Cape Coast, PMB, Ghana. a.faustina@uccsms.edu.gh."}], "LastName": "Adu", "ForeName": "Faustina", "Initials": "F"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Division of Medical Virology, Department of Pathology &amp; Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Anzio Road, Observatory, Cape Town 7925, South Africa. denis.chopera@uct.ac.za."}], "LastName": "Chopera", "ForeName": "Denis", "Initials": "D"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Division of Human Genetics, Department of Pathology &amp; Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Anzio Road, Observatory, Cape Town 7925, South Africa. ambroise.wonkam@uct.ac.za."}], "LastName": "Wonkam", "ForeName": "Ambroise", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Division of Human Genetics, Department of Pathology &amp; Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Anzio Road, Observatory, Cape Town 7925, South Africa. michelle.skelton@uct.ac.za."}], "LastName": "Skelton", "ForeName": "Michelle", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Division of Chemical Pathology, Department of Pathology &amp; Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Anzio Road, Observatory, Cape Town 7925, South Africa. dee.blackhurst@uct.ac.za."}], "LastName": "Blackhurst", "ForeName": "Dee", "Initials": "D"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Division of Human Genetics, Department of Pathology &amp; Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Anzio Road, Observatory, Cape Town 7925, South Africa. collet.dandara@uct.ac.za."}], "LastName": "Dandara", "ForeName": "Collet", "Initials": "C"}], "PublicationTypeList": ["Journal Article", "Research Support, Non-U.S. Gov't"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Molecules", "NlmUniqueID": "100964009", "ISSNLinking": "1420-3049"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Alkynes"}, {"RegistryNumber": "0", "NameOfSubstance": "Benzoxazines"}, {"RegistryNumber": "0", "NameOfSubstance": "Cyclopropanes"}, {"RegistryNumber": "0", "NameOfSubstance": "Cytochrome P-450 CYP2B6 Inhibitors"}, {"RegistryNumber": "0", "NameOfSubstance": "Plant Extracts"}, {"RegistryNumber": "99DK7FVK1H", "NameOfSubstance": "Nevirapine"}, {"RegistryNumber": "EC 1.14.14.1", "NameOfSubstance": "CYP2B6 protein, human"}, {"RegistryNumber": "EC 1.14.14.1", "NameOfSubstance": "Cytochrome P-450 CYP2B6"}, {"RegistryNumber": "JE6H2O27P8", "NameOfSubstance": "efavirenz"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Alkynes"}, {"QualifierName": [], "DescriptorName": "Antiretroviral Therapy, Highly Active"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Benzoxazines"}, {"QualifierName": [], "DescriptorName": "Cyclopropanes"}, {"QualifierName": ["genetics", "metabolism"], "DescriptorName": "Cytochrome P-450 CYP2B6"}, {"QualifierName": ["chemistry", "pharmacology"], "DescriptorName": "Cytochrome P-450 CYP2B6 Inhibitors"}, {"QualifierName": [], "DescriptorName": "Herb-Drug Interactions"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["chemistry"], "DescriptorName": "Magnoliopsida"}, {"QualifierName": ["pharmacology"], "DescriptorName": "Nevirapine"}, {"QualifierName": ["chemistry", "pharmacology"], "DescriptorName": "Plant Extracts"}, {"QualifierName": ["chemistry"], "DescriptorName": "Plants, Medicinal"}], "CoiStatement": "The authors declare no conflict of interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Basavaraj K.H., Navya M.A., Rashmi R. Quality of life in HIV/AIDS. Indian J. Sex. Transm. Dis. 2010;31:75\u201380. doi: 10.4103/0253-7184.74971.", "ArticleIdList": ["10.4103/0253-7184.74971", "PMC3122586", "21716787"]}, {"Citation": "Oguntibeju O.O. Quality of life of people living with HIV and AIDS and antiretroviral therapy. HIV/AIDS. 2012;4:117\u2013124. doi: 10.2147/HIV.S32321.", "ArticleIdList": ["10.2147/HIV.S32321", "PMC3418767", "22893751"]}, {"Citation": "World Health Organization . Antiretroviral Therapy for HIV Infection in Adults and Adolescents. World Health Organization; Geneva, Switzerland: 2010.", "ArticleIdList": ["23741771"]}, {"Citation": "Bhatt N.B., Baudin E., Meggi B., da Silva C., Barrail-Tran A., Furlan V., Grinsztejn B., Bonnet M., Taburet A.M., Jani I.V., et al. Nevirapine or efavirenz for tuberculosis and HIV coinfected patients: Exposure and virological failure relationship. J. Antimicrob. Chemother. 2014;70:225\u2013232. doi: 10.1093/jac/dku348.", "ArticleIdList": ["10.1093/jac/dku348", "PMC4267502", "25239466"]}, {"Citation": "Rodney P., Ndjakani Y., Ceesay F.K., Wilson N.O. Addressing the Impact of HIV/AIDS on Women and Children in Sub-Saharan Africa: PEPFAR, the U.S. Strategy. Afr. Today. 2011;57:64\u201376. doi: 10.2979/AFT.2010.57.1.64.", "ArticleIdList": ["10.2979/AFT.2010.57.1.64"]}, {"Citation": "Yimer G., Amogne W., Habtewold A., Makonnen E., Ueda N., Suda A., Worku A., Haefeli W.E., Burhenne J., Aderaye G., et al. High plasma efavirenz level and CYP2B6 *6 are associated with efavirenz-based HAART-induced liver injury in the treatment of na\u00efve HIV patients from Ethiopia: A prospective cohort study. Pharmacogenom. J. 2012;12:499\u2013506. doi: 10.1038/tpj.2011.34.", "ArticleIdList": ["10.1038/tpj.2011.34", "21862974"]}, {"Citation": "Ward B.A., Gorski J.C., Jones D.R., Hall S.D., Flockhart D.A., Desta Z. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: Implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J. Pharmacol. Exp. Ther. 2003;306:287\u2013300. doi: 10.1124/jpet.103.049601.", "ArticleIdList": ["10.1124/jpet.103.049601", "12676886"]}, {"Citation": "Haas D.W., Gebretsadik T., Mayo G., Menon U.N., Acosta E.P., Shintani A., Floyd M., Stein C.M., Wilkinson G.R. Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African americans. J. Infect. Dis. 2009;199:872\u2013880. doi: 10.1086/597125.", "ArticleIdList": ["10.1086/597125", "PMC2784690", "19239339"]}, {"Citation": "Tsuchiya K., Gatanaga H., Tachikawa N., Teruya K., Kikuchi Y., Yoshino M., Kuwahara T., Shirasaka T., Kimura S., Oka S. Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. Biochem. Biophys. Res. Commun. 2004;319:1322\u20131326. doi: 10.1016/j.bbrc.2004.05.116.", "ArticleIdList": ["10.1016/j.bbrc.2004.05.116", "15194512"]}, {"Citation": "Mugusi S., Ngaimisi E., Janabi M., Minzi O., Bakari M., Riedel K.D., Burhenne J., Lindquist L., Mugusi F., Sandstrom E., et al. Liver enzyme abnormalities and associated risk factors in HIV patients on efavirenz-based HAART with or without tuberculosis co-infection in Tanzania. PLoS ONE. 2012;7 doi: 10.1371/journal.pone.0040180.", "ArticleIdList": ["10.1371/journal.pone.0040180", "PMC3394799", "22808112"]}, {"Citation": "Thomford N.E., Dzobo K., Chopera D., Wonkam A., Skelton M., Blackhurst D., Chirikure S., Dandara C. Pharmacogenomics Implications of Using Herbal Medicinal Plants on African Populations in Health Transition. Pharmaceuticals. 2015;8:637\u2013663. doi: 10.3390/ph8030637.", "ArticleIdList": ["10.3390/ph8030637", "PMC4588186", "26402689"]}, {"Citation": "Kim H.G., Oh M.S. Herbal medicines for the prevention and treatment of Alzheimer\u2019s disease. Curr. Pharm. Des. 2012;18:57\u201375.", "ArticleIdList": ["22316321"]}, {"Citation": "Chien C.F., Wu Y.T., Tsai T.H. Biological analysis of herbal medicines used for the treatment of liver diseases. Biomed. Chromatogr. 2011;25:21\u201338. doi: 10.1002/bmc.1568.", "ArticleIdList": ["10.1002/bmc.1568", "21204110"]}, {"Citation": "Dhiman R.K., Chawla Y.K. Herbal medicines for liver diseases. Dig. Dis. Sci. 2005;50:1807\u20131812. doi: 10.1007/s10620-005-2942-9.", "ArticleIdList": ["10.1007/s10620-005-2942-9", "16187178"]}, {"Citation": "Dahanukar S.A., Kulkarni R.A., Rege N.N. Pharmacology of medicinal plants and natural products. Indian J. Pharmacol. 2000;32:81\u2013118."}, {"Citation": "Efferth T., Koch E. Complex interactions between phytochemicals. The multi-target therapeutic concept of phytotherapy. Curr. Drug Targets. 2011;12:122\u2013132. doi: 10.2174/138945011793591626.", "ArticleIdList": ["10.2174/138945011793591626", "20735354"]}, {"Citation": "Kennedy D., Wightman E. Herbal extracts and phytochemicals: Plant secondary metabolites and the enhancement of human brain function. Adv. Nutr. Int. Rev. J. 2011;2:32\u201350. doi: 10.3945/an.110.000117.", "ArticleIdList": ["10.3945/an.110.000117", "PMC3042794", "22211188"]}, {"Citation": "Koffuor G.A., Woode E., Amaning-Danquah C. Potential Drug Interactions of a Polyherbal Antihypertensive Mixture in Ghana. Pharmacol. Sin. 2011;2:39\u201345."}, {"Citation": "Chen X.W., Serag E.S., Sneed K.B., Liang J., Chew H., Pan S.-Y., Zhou S.-F. Clinical herbal interactions with conventional drugs: From molecules to maladies. Curr. Med. Chem. 2011;18:4836\u20134850. doi: 10.2174/092986711797535317.", "ArticleIdList": ["10.2174/092986711797535317", "21919844"]}, {"Citation": "He S.M., Chan E., Zhou S.F. ADME properties of herbal medicines in humans: Evidence, challenges and strategies. Curr. Pharm. Des. 2011;17:357\u2013407. doi: 10.2174/138161211795164194.", "ArticleIdList": ["10.2174/138161211795164194", "21385154"]}, {"Citation": "Ingelman-Sundberg M. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: The past, present and future. Trends Pharmacol. Sci. 2004;25:193\u2013200. doi: 10.1016/j.tips.2004.02.007.", "ArticleIdList": ["10.1016/j.tips.2004.02.007", "15063083"]}, {"Citation": "Turpeinen M., Zanger U.M. Cytochrome P450 2B6: Function, genetics, and clinical relevance. Drug Metab. Drug Interact. 2012;27:185\u2013197. doi: 10.1515/dmdi-2012-0027.", "ArticleIdList": ["10.1515/dmdi-2012-0027", "23152403"]}, {"Citation": "Mo S.L., Liu Y.H., Duan W., Wei M.Q., Kanwar J.R., Zhou S.F. Substrate specificity, regulation, and polymorphism of human cytochrome P450 2B6. Curr. Drug Metab. 2009;10:730\u2013753. doi: 10.2174/138920009789895534.", "ArticleIdList": ["10.2174/138920009789895534", "19702527"]}, {"Citation": "Wang H., Tompkins L.M. CYP2B6: New insights into a historically overlooked cytochrome P450 isozyme. Curr. Drug Metab. 2008;9:598\u2013610. doi: 10.2174/138920008785821710.", "ArticleIdList": ["10.2174/138920008785821710", "PMC2605793", "18781911"]}, {"Citation": "Turpeinen M., Raunio H., Pelkonen O. The functional role of CYP2B6 in human drug metabolism: Substrates and inhibitors in vitro, in vivo and in silico. Curr. Drug Metab. 2006;7:705\u2013714. doi: 10.2174/138920006778520633.", "ArticleIdList": ["10.2174/138920006778520633", "17073575"]}, {"Citation": "Zanger U.M., Klein K. Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): Advances on polymorphisms, mechanisms, and clinical relevance. Front. Genet. 2013;4:24. doi: 10.3389/fgene.2013.00024.", "ArticleIdList": ["10.3389/fgene.2013.00024", "PMC3588594", "23467454"]}, {"Citation": "McGinnity D.F., Tucker J., Trigg S., Riley R.J. Prediction of CYP2C9-mediated drug-drug interactions: A comparison using data from recombinant enzymes and human hepatocytes. Drug Metab. Dispos. 2005;33:1700\u20131707. doi: 10.1124/dmd.105.005884.", "ArticleIdList": ["10.1124/dmd.105.005884", "16081671"]}, {"Citation": "Abourashed E. Bioavailability of Plant-Derived Antioxidants. Antioxidants. 2013;2:309\u2013325. doi: 10.3390/antiox2040309.", "ArticleIdList": ["10.3390/antiox2040309", "PMC4665521", "26784467"]}, {"Citation": "Stout C.W., Weinstock J., Homoud M.K., Wang P.J.N., Estes A.M., Link M.S. Herbal medicine: Beneficial effects, side effects, and promising new research in the treatment of arrhythmias. Curr. Cardiol. Rep. 2003;5:395\u2013401.", "ArticleIdList": ["12917055"]}, {"Citation": "Djuv A., Nilsen O.G., Steinsbekk A. The co-use of conventional drugs and herbs among patients in Norwegian general practice: A cross-sectional study. BMC Complement. Altern. Med. 2013;13 doi: 10.1186/1472-6882-13-295.", "ArticleIdList": ["10.1186/1472-6882-13-295", "PMC4228482", "24171723"]}, {"Citation": "Fugh-berman A. Herb-drug interactions. Lancet. 2000;355:134\u2013138. doi: 10.1016/S0140-6736(99)06457-0.", "ArticleIdList": ["10.1016/S0140-6736(99)06457-0", "10675182"]}, {"Citation": "Chen X.W., Sneed K.B., Pan S.Y., Cao C., Kanwar R.J., Chew H., Zhou S.F. Herb-drug interactions and mechanistic and clinical considerations. Curr. Drug Metab. 2012;13:640\u2013651. doi: 10.2174/1389200211209050640.", "ArticleIdList": ["10.2174/1389200211209050640", "22292789"]}, {"Citation": "Huang S.M., Strong J.M., Zhang L., Reynolds K.S., Nallani S., Temple R., Abraham S., Al Habet S., Baweja R.K., Burckart G.J., et al. New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. J. Clin. Pharmacol. 2008;48:662\u2013670. doi: 10.1177/0091270007312153.", "ArticleIdList": ["10.1177/0091270007312153", "18378963"]}, {"Citation": "Bjornsson T.D., Callaghan J.T., Einolf H.J., Fischer V., Gan L., Grimm S., Kao J., King S.P., Miwa G., Ni L., et al. The conduct of in vitro and in vivo drug-drug interaction studies: A PhRMA perspective. J. Clin. Pharmacol. 2003;43:443\u2013469.", "ArticleIdList": ["12751267"]}, {"Citation": "Zhang L., Zhang Y.D., Zhao P., Huang S.M. Predicting drug-drug interactions: An FDA perspective. AAPS J. 2009;11:300\u2013306. doi: 10.1208/s12248-009-9106-3.", "ArticleIdList": ["10.1208/s12248-009-9106-3", "PMC2691466", "19418230"]}, {"Citation": "European Medicines Agency . Guideline on the Investigation of Drug Interactions. Committee for Human Medicinal Products (CHMP); London, UK: 2015. pp. 1\u201359. CPMP/EWP/560/560/95/Rev."}, {"Citation": "Manda V.K., Dale O.R., Awortwe C., Ali Z., Khan I., Walker L., Khan S.I. Evaluation of drug interaction potential of Labisia pumila (Kacip Fatimah) and its constituents. Front. Pharmacol. 2014;5 doi: 10.3389/fphar.2014.00178.", "ArticleIdList": ["10.3389/fphar.2014.00178", "PMC4126480", "25152732"]}, {"Citation": "Obach R.S., Walsky R.L., Venkatakrishnan K. Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug-drug interactions. Drug Metab. Dispos. 2007;35:246\u2013255. doi: 10.1124/dmd.106.012633.", "ArticleIdList": ["10.1124/dmd.106.012633", "17093004"]}, {"Citation": "Berry L.M., Zhao Z. An examination of IC50 and IC50-shift experiments in assessing time-dependent inhibition of CYP3A4, CYP2D6 and CYP2C9 in human liver microsomes. Drug Metab. Lett. 2008;2:51\u201359. doi: 10.2174/187231208783478407.", "ArticleIdList": ["10.2174/187231208783478407", "19356071"]}, {"Citation": "Li P., Lu C., Balani S.K., Gan L.-S. A refined cytochrome P540 IC50 shift assay for reliably identifying CYP3A time-dependent inhibitors. Drug Metab. Dispos. 2011;39:1054\u20131057. doi: 10.1124/dmd.111.038208.", "ArticleIdList": ["10.1124/dmd.111.038208", "21393461"]}, {"Citation": "Grimm S.W., Einolf H.J., Hall S.D., He K., Lim H.K., Ling K.H.J., Lu C., Nomeir A., Seibert E., Skordos K.W., et al. The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: A perspective of the Pharmaceutical Research and Manufacturers of America. Drug Metab. Dispos. 2009;37:1355\u20131370. doi: 10.1124/dmd.109.026716.", "ArticleIdList": ["10.1124/dmd.109.026716", "19359406"]}, {"Citation": "Adinortey M.B., Sarfo J.K., Quayson E.T., Weremfo A., Adinortey C.A. Phytochemical Screening, Proximate and Mineral Composition of Launaea taraxacifolia Leaves. Res. J. Med. Plant. 2012;6:171\u2013179. doi: 10.3923/rjmp.2012.171.179.", "ArticleIdList": ["10.3923/rjmp.2012.171.179"]}, {"Citation": "Ocama P., Katwere M., Piloya T., Feld J., Opio K.C., Kambugu A., Katabira E., Thomas D., Colebunders R., Ronald A. The spectrum of liver diseases in HIV infected individuals at an HIV treatment clinic in Kampala, Uganda. Afr. Health Sci. 2008;8:8\u201312.", "ArticleIdList": ["PMC2408539", "19357726"]}, {"Citation": "Price J.C., Thio C.L. Liver disease in the HIV-infected individual. Clin. Gastroenterol. Hepatol. 2010;8:1002\u20131012. doi: 10.1016/j.cgh.2010.08.024.", "ArticleIdList": ["10.1016/j.cgh.2010.08.024", "PMC2997131", "20851211"]}, {"Citation": "Husain N.E.O., Ahmed M.H. Managing dyslipidemia in HIV/AIDS patients: Challenges and solutions. HIV/AIDS. 2015;7:1\u201310.", "ArticleIdList": ["PMC4274137", "25565897"]}, {"Citation": "Lo J. Dyslipidemia and lipid management in HIV-infected patients. Curr. Opin. Endocrinol. Diabetes Obes. 2011;18:144\u2013147. doi: 10.1097/MED.0b013e328344556e.", "ArticleIdList": ["10.1097/MED.0b013e328344556e", "PMC3154840", "21297466"]}, {"Citation": "Feeney E.R., Mallon P.W.G. HIV and HAART-Associated Dyslipidemia. Open Cardiovasc. Med. J. 2011;5:49\u201363. doi: 10.2174/1874192401105010049.", "ArticleIdList": ["10.2174/1874192401105010049", "PMC3106351", "21643501"]}, {"Citation": "Da Neto S.P.L.F., das Neves M.B., Ribeiro-Rodrigues R., Page K., Miranda A.E. Dyslipidemia and fasting glucose impairment among HIV patients three years after the first antiretroviral regimen in a Brazilian AIDS outpatient clinic. Braz. J. Infect. Dis. 2013;17:438\u2013443. doi: 10.1016/j.bjid.2012.12.006.", "ArticleIdList": ["10.1016/j.bjid.2012.12.006", "PMC9428045", "23735423"]}, {"Citation": "Estrada V., Portilla J. Dyslipidemia related to antiretroviral therapy. AIDS Rev. 2011;13:49\u201356.", "ArticleIdList": ["21412389"]}, {"Citation": "Rastogi H., Jana S. Evaluation of Inhibitory Effects of Caffeic acid and Quercetin on Human Liver Cytochrome P450 Activities. Phytother. Res. 2014;28:1873\u20131878. doi: 10.1002/ptr.5220.", "ArticleIdList": ["10.1002/ptr.5220", "25196644"]}, {"Citation": "Baer-Dubowska W., Szaefer H., Krajka-Kuzniak V. Inhibition of murine hepatic cytochrome P450 activities by natural and synthetic phenolic compounds. Xenobiotica. 1998;28:735\u2013743. doi: 10.1080/004982598239155.", "ArticleIdList": ["10.1080/004982598239155", "9741952"]}, {"Citation": "Huynh H.T., Teel R.W. Effects of plant-derived phenols on rat liver cytochrome P450 2B1 activity. Anticancer Res. 2002;22:1699\u20131703.", "ArticleIdList": ["12168856"]}, {"Citation": "Nagao T., Komine Y., Soga S., Meguro S., Hase T., Tanaka Y., Tokimitsu I. Ingestion of a tea rich in catechins leads to a reduction in body fat and malondialdehyde-modified LDL in men. Am. J. Clin. Nutr. 2005;81:122\u2013129.", "ArticleIdList": ["15640470"]}, {"Citation": "Kannan R.R.R., Arumugam R., Thangaradjou T., Anantharaman P. Phytochemical constituents, antioxidant properties and p-coumaric acid analysis in some seagrasses. Food Res. Int. 2013;54:1229\u20131236. doi: 10.1016/j.foodres.2013.01.027.", "ArticleIdList": ["10.1016/j.foodres.2013.01.027"]}, {"Citation": "Farag M.A., Wessjohann L.A. Metabolome classification of commercial Hypericum perforatum (St. John\u2019s Wort) preparations via UPLC-qTOF-MS and chemometrics. Planta Med. 2012;78:488\u2013496. doi: 10.1055/s-0031-1298170.", "ArticleIdList": ["10.1055/s-0031-1298170", "22271082"]}, {"Citation": "Berry L.M., Zhao Z., Lin M.J. Dynamic Modeling of Cytochrome P450 Inhibition in vitro: Impact of Inhibitor Depletion on IC50 Shifts. Drug Metab. Dispos. 2013;41:1433\u20131441. doi: 10.1124/dmd.113.051508.", "ArticleIdList": ["10.1124/dmd.113.051508", "23649703"]}, {"Citation": "Awortwe C., Bouic P.J., Masimirembwa C.M., Rosenkranz B. Inhibition of Major Drug Metabolizing CYPs by Common Herbal Medicines used by HIV/AIDS Patients in Africa\u2014Implications for Herb-Drug Interactions. Drug Metab. Lett. 2013;7:83\u201395. doi: 10.2174/1872312808666140129123210.", "ArticleIdList": ["10.2174/1872312808666140129123210", "PMC4354708", "24475926"]}], "ReferenceList": []}], "History": [{"Year": "2015", "Month": "12", "Day": "23"}, {"Year": "2016", "Month": "1", "Day": "25"}, {"Year": "2016", "Month": "2", "Day": "2"}, {"Year": "2016", "Month": "2", "Day": "19", "Hour": "6", "Minute": "0"}, {"Year": "2016", "Month": "2", "Day": "20", "Hour": "6", "Minute": "0"}, {"Year": "2016", "Month": "10", "Day": "25", "Hour": "6", "Minute": "0"}, {"Year": "2016", "Month": "2", "Day": "16"}], "PublicationStatus": "epublish", "ArticleIdList": ["26891286", "PMC6273559", "10.3390/molecules21020211", "molecules21020211"]}}], "PubmedBookArticle": []}